G1 Therapeutics Inc
General ticker "GTHX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $373.9M
G1 Therapeutics Inc follows the US Stock Market performance with the rate: 40.0%.
Estimated limits based on current volatility of 0.1%: low 7.14$, high 7.15$
Factors to consider:
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.62$, 4.27$]
- 2024-12-30 to 2025-12-30 estimated range: [2.33$, 5.67$]
Financial Metrics affecting the GTHX estimates:
- Negative: Operating Income to Revenue ratio of -0.32 <= 0.01
- Negative: Non-GAAP EPS of -0.95 <= 0.11
- Negative: negative Net Income
- Negative: Operating Cash Flow per share of -0.74 <= 0.22
- Negative: Industry Operating Cash Flow per share (median) of -1.60 <= 0.31
Short-term GTHX quotes
Long-term GTHX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $31.48MM | $51.30MM | $82.51MM |
| Operating Expenses | $173.93MM | $187.48MM | $122.04MM |
| Operating Income | $-142.46MM | $-136.18MM | $-39.53MM |
| Non-Operating Income | $-4.97MM | $-9.68MM | $-5.33MM |
| Interest Expense | $4.67MM | $10.43MM | $10.04MM |
| R&D Expense | $76.22MM | $83.32MM | $43.71MM |
| Income(Loss) | $-147.43MM | $-145.86MM | $-44.85MM |
| Taxes | $0.93MM | $1.70MM | $3.12MM |
| Profit(Loss) | $-148.35MM | $-147.56MM | $-47.97MM |
| Stockholders Equity | $143.54MM | $68.75MM | $35.39MM |
| Assets | $254.09MM | $187.97MM | $121.54MM |
| Operating Cash Flow | $-132.11MM | $-128.62MM | $-38.34MM |
| Investing Cash Flow | $0.00MM | $-50.53MM | $2.81MM |
| Financing Cash Flow | $145.86MM | $52.49MM | $-26.91MM |
| Earnings Per Share* | $-3.54 | $-3.38 | $-0.93 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.